Scientists find a protein that inhibits Ebola from reaching out to infect neighboring cells

Scientists at the University of Pennsylvania School of Veterinary Medicine have identified a protein, ISG15, that inhibits the Ebola virus from budding, the process by which viruses escape from cells and spread to infect neighboring cells.

This study shows for the first time how ISG15 slows the spread of Ebola virus budding, an observation that could help explain how ISG15 successfully inhibits other viruses, including HIV-1 and herpes simplex virus type I. The findings, reported in the current issue of the Proceedings of the National Academy of Sciences, offer the promise of future treatments for Ebola outbreaks that now prove fatal for as many as 90 percent of victims.

According to the Penn Vet research team, ISG15 inhibits budding in an indirect way, by blocking the behavior of a particular host cell protein which is used by Ebola and other viruses to efficiently escape from cells. ISG15 specifically inhibits the host protein, Nedd4, used by the viral protein VP40 to escape from cells and allow for virus spread.

“Inhibit the proteins used by a virus to reproduce and you are inhibiting the virus itself,” Ronald Harty, lead author of the study and associate professor in the Department of Pathobiology at Penn Vet, said. “Without host Nedd4, the Ebola virus still buds and attacks, but it doesn’t bud as well. The long-term goal of our research is to understand the interplay between host and virus, with the hope of creating an anti-viral drug or inhibitor, much like how Tamiflu doesn’t cure the flu but slows down the viral process,” Harty said. “The drug would be designed to dampen or slow down viral budding to allow an infected person’s immune system to fight back.”

The Ebola virus VP40 protein is the key player in the process of virus assembly and release from infected cells. VP40 buds from mammalian cells independent of other viral proteins, and efficient release of VP40 virus-like particles, VLPs, requires interactions with host proteins such as tsg101 and Nedd4, an E3 ubiquitin ligase. Ubiquitin itself is thought to be exploited by Ebola virus to facilitate efficient virus egress.

The study showed that expression of free ISG15, or the ISGylation System, UbE1L and UbcH8, inhibits budding of Ebola virus VP40 VLPs. Addressing the molecular mechanism of this inhibition, the researchers demonstrated that ISG15 interacts with Nedd4 ubiquitin ligase and inhibits ubiquitination of VP40, thus blocking budding of VP40 VLPs. These data provide evidence of antiviral activity of ISG15 against Ebola virus and suggest a mechanism of action involving disruption of Nedd4 function and subsequent ubiquitination of VP40.

This newest study has extended the team’s knowledge of the reproductive process of Ebola and other viruses with similar reproductive mechanisms. Prior research by Harty and his team had shown that a sequence of four amino acids in VP40 was critical to the spread of the Ebola virus. VP40 appeared to be the necessary protein component to begin the viral budding process. The findings allowed researchers to target VP40 as a key to viral reproduction.

Penn researchers performed this research using only the VP40 protein found in the Ebola and other viruses. VP40 is not harmful in vitro, yet forms a virus-like particle, a unique phenomenon that allows for study of viral behavior without the danger associated with the virus.

Source: University of Pennsylvania

Related stories:

Vaccine for Ebola virus
One of the world’s deadliest diseases, caused by the Ebola virus, may finally be preventable thanks to US and Canadian researchers, who have successfully tested several Ebola vaccines in primates and are now looking to adapt them for human use.
Combination vaccine protects monkeys from ebola and Marburg viruses
An experimental, combination vaccine against Ebola and Marburg viruses using virus-like particles (VLPs) provides complete protection against infection in monkeys. Researchers from the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) report their results today (Feb. 26) at the 2008 ASM Biodefense and Emerging Diseases Research Meeting in Baltimore, MD.
Emerging infectious diseases on the rise: Next target 'hotspot' predicted
It’s not just your imagination. Providing the first-ever definitive proof, a team of scientists has shown that emerging infectious diseases such as HIV, Severe Acute Respiratory Syndrome (SARS), West Nile virus and Ebola are indeed on the rise. The team – including University of Georgia professor John Gittleman and scientists from the Consortium for Conservation Medicine, the Institute of Zoology (London) and Columbia University – recently published their findings in leading scientific journal Nature.
Study garners unique mating photos of wild gorillas
Scientists from the Wildlife Conservation Society and Max Planck Institute for Evolutionary Anthropology have released the first known photographs of gorillas performing face-to-face copulation in the wild. This is the first time that western gorillas have been observed and photographed mating in such a manner.
Evolutionary battle scars' identify enhanced antiviral activity
Rapid evolution of a protein produced by an immunity gene is associated with increased antiviral activity in humans, a finding that suggests evolutionary biology and virology together can accelerate the discovery of viral-defense mechanisms, according to researchers at Fred Hutchinson Cancer Research Center in Seattle, Washington.
Ebola virus disarmed by excising a single gene
The deadly Ebola virus, an emerging public health concern in Africa and a potential biological weapon, ranks among the most feared of exotic pathogens.
Cells use Velcro-like mechanism to keep viruses from spreading
Like mobsters, cells keep their friends close and their enemies — at least some of them — closer. According to new results from HIV researchers at Rockefeller University, one way that human cells prevent certain viruses from raging out of control is by blocking new viral particles from ever leaving an infected cell’s surface. And, they believe, HIV thrives in part because it has evolved the ability to get around this obstacle.
New genetic lineage of Ebola virus discovered in great apes
Since its discovery 30 years ago, Ebolavirus has struck repeatedly in several epidemics breaking out mainly in Central Africa. Gorillas and chimpanzees are also victims of the violent haemorrhagic fever attacks the virus triggers. With the aim of understanding more of Ebola’s action mechanisms, scientists collect viral RNA samples from infected individuals at each outbreak. Hitherto it was only possible to analyse genetic sequences isolated from humans.

News discussion:

Medicine & Health news